Dexcom Inc. Files 8-K on Director Changes and Compensation
Ticker: DXCM · Form: 8-K · Filed: Dec 22, 2025 · CIK: 1093557
| Field | Detail |
|---|---|
| Company | Dexcom INC (DXCM) |
| Form Type | 8-K |
| Filed Date | Dec 22, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $1,150,000, $7,500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, board-of-directors
Related Tickers: DXCM
TL;DR
Dexcom filed an 8-K for director changes and exec comp updates. Keep an eye on governance.
AI Summary
On December 19, 2025, Dexcom, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes the election of new directors and updates to compensatory arrangements for certain officers, though specific names and dollar amounts are not provided in this excerpt.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing appears to be routine corporate governance updates and does not indicate significant financial distress or operational issues.
Key Numbers
- 20251219 — Report Date (Date of earliest event reported)
- 000-51222 — SEC File Number (Registrant's SEC File Number)
Key Players & Entities
- DEXCOM INC (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- San Diego, CA (location) — Principal Executive Offices
FAQ
What specific changes were made to the board of directors?
The filing indicates the election of directors, but specific names and details of the changes are not provided in this excerpt.
Were there any new executive appointments?
The filing mentions the appointment of certain officers as part of the report's item information, but specific details are not included here.
What is the nature of the updates to compensatory arrangements?
The filing notes updates to compensatory arrangements for certain officers, but the specifics of these arrangements are not detailed in this excerpt.
What is the principal business address of Dexcom, Inc.?
The principal executive offices are located at 6340 Sequence Drive, San Diego, CA 92121.
What is the fiscal year end for Dexcom, Inc.?
The fiscal year end for Dexcom, Inc. is December 31.
Filing Stats: 825 words · 3 min read · ~3 pages · Grade level 9.9 · Accepted 2025-12-22 16:35:12
Key Financial Figures
- $0.001 — ange on Which Registered Common Stock, $0.001 Par Value Per Share DXCM Nasdaq Global
- $1,150,000 — providing for an annual base salary of $1,150,000 and annual target bonus opportunity equ
- $7,500,000 — ricted stock units with a fair value of $7,500,000, vesting annually over the three years
Filing Documents
- dxcm-20251219.htm (8-K) — 30KB
- dxcm20251219-exhibit101.htm (EX-10.1) — 21KB
- dxcm-20251219_g1.jpg (GRAPHIC) — 108KB
- dxcm-20251219_g2.jpg (GRAPHIC) — 6KB
- 0001093557-25-000291.txt ( ) — 426KB
- dxcm-20251219.xsd (EX-101.SCH) — 2KB
- dxcm-20251219_lab.xml (EX-101.LAB) — 21KB
- dxcm-20251219_pre.xml (EX-101.PRE) — 12KB
- dxcm-20251219_htm.xml (XML) — 3KB
01. FINANCIAL STATEMENTS AND EXHIBITS
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits. Number Description 10.1* Offer Letter, effective January 1, 2026, by and between DexCom, Inc. and Jacob S. Leach. 104 Cover Page Interactive Data File (formatted as Inline XBRL) * Represents a management contract or compensatory plan, contract or arrangement.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DEXCOM, INC. By: /s/ JEREME M. SYLVAIN Jereme M. Sylvain Executive Vice President, Chief Financial Officer Date: December 22, 2025